![Roberto Solari](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Roberto Solari
Private Equity Investor bei Brandon Capital Partners Pty Ltd.
Ursprung des Netzwerks ersten Grades von Roberto Solari
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Brandon Capital Partners Pty Ltd.
![]() Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.
36
| Private Company | Investment Managers | 36 |
Auspherix Ltd.
![]() Auspherix Ltd. BiotechnologyHealth Technology Auspherix Ltd. operates as an early stage anti-infectives company which develops novel antibiotics to treat resistant bacterial diseases. The firm uses a library screening approach to identify drugs with novel mechanisms of action as antibiotics. The company was founded by Ian Charles and Dagmar Alber in 2013 and is headquartered in Stevenage, the United Kingdom.
7
| Extinct | Biotechnology | 7 |
Myricx Pharma Ltd.
![]() Myricx Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom.
4
| Holding Company | Miscellaneous Commercial Services | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Roberto Solari
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Miscellaneous Commercial Services | Director/Board Member Chief Operating Officer Founder | |
AusBiotech Ltd.
![]() AusBiotech Ltd. Miscellaneous Commercial ServicesCommercial Services AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Pathios Therapeutics Ltd.
![]() Pathios Therapeutics Ltd. BiotechnologyHealth Technology Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member Founder Founder | |
Imperial College London | College/University | Masters Business Admin Masters Business Admin Corporate Officer/Principal | |
Global Kinetics Pty Ltd.
![]() Global Kinetics Pty Ltd. Medical SpecialtiesHealth Technology Global Kinetics Pty Ltd. provides point of care measurement and reporting of Parkinson's disease motor symptoms. Its product includes Personal KinetiGraph (PKG), a wrist worn medical device which reminds the patient when they have taken Levodopa medication as prescribed by doctor. The company was founded by Robert Griffiths and Malcolm Horne in 2007 and is headquartered in Melbourne, Australia. | Medical Specialties | Chairman Director/Board Member Director/Board Member | |
University College London | College/University | Doctorate Degree Doctorate Degree | |
Denteric Pty Ltd.
![]() Denteric Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Denteric Pty Ltd. is a biotechnology company focused on oral health. It provides developing vaccines for treating and preventing severe periodontal disease. The company was founded by Eric C. Reynolds and is headquartered in Melbourne, Australia. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Q-Sera Pty Ltd.
![]() Q-Sera Pty Ltd. Medical SpecialtiesHealth Technology Q-Sera Pty Ltd. develops, manufactures and markets blood serum collection tubes. The company was founded in 2012 and is headquartered in Melbourne, Australia. | Medical Specialties | Director/Board Member Director/Board Member | |
Elastagen Pty Ltd.
![]() Elastagen Pty Ltd. Medical SpecialtiesHealth Technology Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia. | Medical Specialties | Director/Board Member Chief Executive Officer | |
University of Adelaide | College/University | Graduate Degree Doctorate Degree | |
EBR SYSTEMS, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
Cardiora Pty Ltd.
![]() Cardiora Pty Ltd. Investment Trusts/Mutual FundsMiscellaneous Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia. | Investment Trusts/Mutual Funds | Director/Board Member Director/Board Member | |
University of Melbourne
![]() University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | College/University | Doctorate Degree Graduate Degree | |
Respirion Pharmaceuticals Pty Ltd.
![]() Respirion Pharmaceuticals Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Respirion Pharmaceuticals Pty Ltd. operates as a biotechnology firm. It focuses on development new treatments for respiratory diseases. The company was founded by Barry Clements in 2018 and is headquartered in Iluka, Australia. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
QUE Oncology, Inc.
![]() QUE Oncology, Inc. Pharmaceuticals: MajorHealth Technology QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
OncoRes Medical Pty Ltd.
![]() OncoRes Medical Pty Ltd. Medical SpecialtiesHealth Technology OncoRes Medical Pty Ltd. develops an imaging medical device which provides micro-scale images of tissue stiffness and elasticity information to surgeons. The company is headquartered in Nedlands, Australia. | Medical Specialties | Chairman Chief Executive Officer | |
Longas Technologies Pty Ltd.
![]() Longas Technologies Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Longas Technologies Pty Ltd. is engaged in developing next generation sequencing (NGS) technologies. The company was founded by Ian Charles, Aaron Darling, and Catherine Burke in 2015 and is headquartered in Sydney, Australia. | Miscellaneous Commercial Services | Chairman Founder | |
Maxygen ApS | Corporate Officer/Principal | ||
Rochester Christian University | College/University | Undergraduate Degree | |
University of Virginia | College/University | Doctorate Degree | |
LEO Pharma A/S
![]() LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Novo Holdings AS (Denmark)
![]() Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal | |
Novo Seeds
![]() Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal | |
Avilex Pharma ApS
![]() Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman | |
Caerus Consulting AS
![]() Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Pharmaceuticals: Major | Director/Board Member | |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Oxular Ltd.
![]() Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Biotechnology | Director/Board Member | |
STORM Therapeutics Ltd.
![]() STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Acesion Pharma ApS
![]() Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Touchstone Innovations Investment Management Ltd.
![]() Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Director/Board Member | |
Pulmocide Ltd.
![]() Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Enterprise Therapeutics Ltd.
![]() Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Biotechnology | Director/Board Member | |
University of Bath | College/University | Doctorate Degree | |
Contera Pharma ApS
![]() Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Australian Graduate School of Entrepreneurship | College/University | Graduate Degree | |
Azura Ophthalmics Pty Ltd.
![]() Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | Medical Specialties | Director/Board Member | |
Athena Medicines Pty Ltd. | Director/Board Member | ||
Medical Research Commercialisation Fund Trust
![]() Medical Research Commercialisation Fund Trust Investment ManagersFinance Medical Research Commercialisation Fund Trust invests in life science companies located in Australia. The fund focuses on companies operating in the fields of medical research institutes and allied research hospitals. It provides seed and early stage financing in project investment of up to $0.02 million, at the stage of company formation invests up to $4 million and also makes follow-on investments of up to $2 million. It seeks co-investment with other investors for technologies with larger capital requirements. | Investment Managers | Chief Executive Officer | |
Australian Investment Council
![]() Australian Investment Council Miscellaneous Commercial ServicesCommercial Services Australian Investment Council is an Australian private company located in Sydney. The firm operates as an association. Navleen Prasad has been the CEO since 2022. | Miscellaneous Commercial Services | Director/Board Member | |
Certa Therapeutics Pty Ltd.
![]() Certa Therapeutics Pty Ltd. BiotechnologyHealth Technology Certa Therapeutics Pty Ltd. operates as biotechnology company. The firm develops drugs for treatment for kidney disease. The company was founded by Darren James Kelly and is headquartered in Melbourne, Australia. | Biotechnology | Director/Board Member | |
PharmaVentures Ltd.
![]() PharmaVentures Ltd. Investment ManagersFinance Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom. | Investment Managers | Corporate Officer/Principal | |
MetabloQ Pty Ltd.
![]() MetabloQ Pty Ltd. BiotechnologyHealth Technology MetabloQ Pty Ltd. develops drugs for cancer treatment. It treats triple-negative breast cancer, prostate cancer and melanoma cancer diseases. The company was founded in 2016 and is headquartered in Melbourne, Australia. | Biotechnology | Chairman | |
Ankere Therapeutics
![]() Ankere Therapeutics BiotechnologyHealth Technology Ankere Therapeutics develops therapeutics for inflammatory diseases. The Australian company was founded by Stuart Pitson, Bernard Flynn. Bernard Flynn has been the CEO since incorporation. | Biotechnology | Director/Board Member |
Statistik
International
Australien | 21 |
Vereinigtes Königreich | 16 |
Dänemark | 9 |
Vereinigte Staaten | 5 |
Irland | 2 |
Sektoral
Health Technology | 28 |
Consumer Services | 10 |
Commercial Services | 7 |
Finance | 6 |
Miscellaneous | 2 |
Operativ
Director/Board Member | 129 |
Corporate Officer/Principal | 36 |
Private Equity Investor | 34 |
Chief Executive Officer | 24 |
Chairman | 21 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Julie Cherrington | 32 |
J. Read | 27 |
Chris Nave | 24 |
Bobby G. Soni | 23 |
Jonathan Leslie Tobin | 19 |
Stephen Thompson | 18 |
Christopher Martin | 18 |
David Fisher | 12 |
Ian Charles | 10 |
Thomas Mccarthy | 7 |
Michael Bettess | 6 |
Robert Daniels | 6 |
Katharine Giles | 6 |
Andrea W. Tobias | 5 |
Ingmar Wahlqvist | 5 |
- Börse
- Insiders
- Roberto Solari
- Unternehmensverbindungen